Genetic polymorphisms associated with risk of venous thromboembolism in multiple myeloma patients treated with thalidomide.

Warning

This publication doesn't include Faculty of Sports Studies. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

ALMÁŠI Martina ŠEVČÍKOVÁ Sabina SLABÝ Ondřej ŠVÁCHOVÁ Hana POUR Luděk KAISAROVA Petra HÁJEK Roman

Year of publication 2011
Type Conference abstract
MU Faculty or unit

Faculty of Medicine

Citation
Description Venous thromboembolism (VTE) is a common side-effect of thalidomide treatment in patients with multiple myeloma (MM). In our retrospective study, we analyzed candidate single-nucleotide polymorphisms (SNPs) - CINP (rs7011), CETP (rs289747), ALDH1A1 (rs610529), CDKN1A (rs3829963), GAN (rs2608555), VEGF (rs699947) and ALDH1A1 (rs168351). Further studies are needed to confirm the initial analysis that provided predictive information of genetic variations in myeloma patients that may influence risk of VTE.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info